Ligachem Bioscience Achieves Development Milestone in ADC Platform Partnership with Ono Pharmaceutical
核心洞察
Ligachem Bioscience (搜索) received a development milestone payment from Japan's Ono Pharmaceutical following successful progress in their ADC platform technology transfer agreement signed in October 2024.
The milestone follows the completion of first target designation in March 2025 and demonstrates that Ligachem's proprietary "Conjugall (搜索)" ADC platform meets global pharmaceutical development standards.
The achievement validates the scalability and competitiveness of Ligachem's ADC technology, with additional milestones expected from multiple global partnerships throughout 2026.
Ligachem Bioscience (搜索) has achieved a significant development milestone in its antibody-drug conjugate (ADC) platform partnership with Japan's Ono Pharmaceutical Industries, marking successful progress in their technology transfer collaboration that began in October 2024.
The South Korean biotechnology company announced on January 8 that it is scheduled to receive a milestone payment related to the ADC platform technology transfer agreement. This achievement represents a follow-up milestone to the initial ADC platform technology transfer and joint research contract established between the two companies last year.
Platform Technology Demonstrates Global Standards
The milestone achievement stems from successful joint research utilizing Ligachem Bioscience (搜索)'s proprietary ADC platform "Conjugall (搜索)" for candidate discovery and development. The companies completed their first target designation in March 2025, achieving an initial milestone shortly after contract signing. Since then, development of the corresponding target-based ADC candidate has progressed according to the planned schedule, meeting requirements for additional milestone generation.
While the specific size and detailed terms of the milestone remain contractually confidential, industry observers view this achievement as evidence that Ligachem's ADC platform technology meets the development standards and schedules required by global pharmaceutical companies while maintaining stable operational performance.
Leadership Emphasizes Strategic Significance
Park Sejin, CEO of Ligachem Bioscience (搜索), emphasized the broader implications of this milestone beyond immediate financial benefits. "This milestone payment is more than a one-time profit; it reaffirms the strong trust between us and Ono Pharmaceutical, as well as the outstanding scalability of our ADC platform technology," Park stated.
The CEO highlighted that receiving this milestone at the start of the new year serves as an indicator that Ligachem's commitment to "performance-driven R&D" is being steadily fulfilled. Park expressed the company's intention to continue enhancing shareholder value and solidifying its position as a global leader in ADCs through ongoing pipeline advancement and increased technology revenue.
Expanding Global Partnership Portfolio
Beyond the Ono Pharmaceutical collaboration, Ligachem Bioscience (搜索) is currently engaged in joint development of ADC pipelines and technology transfer agreements with multiple global pharmaceutical companies. The company is approaching milestone achievements for several pipeline projects with other global partners, indicating the broad applicability and market acceptance of its ADC platform technology.
The company anticipates that additional milestones will continue throughout 2026 following step-by-step development progress across its various partnerships. This expectation reflects confidence in the platform's ability to meet diverse development requirements across multiple therapeutic programs and global pharmaceutical collaborations.
Ligachem expects that the value of its ADC platform technology and development outcomes will accelerate throughout this year, positioning the company for continued growth in the competitive ADC therapeutics market.